Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: Report of the neuraminidase inhibitor susceptibility network

Journal of Clinical Microbiology

Volumn 41, Issue 2, 2003, Pages 742-750

  Wetherall, N T ^a,g   Trivedi, T ^b   Zeller, J ^a   Hodges Savola, C ^a   McKimm Breschkin, J L ^d   Zambon, M ^c   Hayden, F G ^e,f  

^a ViroMed Laboratories Inc Minnesota   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d CSIRO   (Australia)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g Cambridge Biomedical Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; INFLUENZA VIRUS; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; ORTHOMYXOVIRIDAE; SUBSTRATE SPECIFICITY;

ANIMALIA; INFLUENZA VIRUS; INFLUENZAVIRUS A; INFLUENZAVIRUS B; RNA VIRUSES;

EID: 12244295453     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.2.742-750.2003     Document Type: Article

References (21)

1. Babu, Y. S., P. Chand, S. Bantia, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchinson, A. J. Elliott, C. D. Parker, S. L. Ananth, L. L. Horn, G. W. Laver, and J. A. Montgomery. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43:3482-3486.
2. Barnett, J. M., A. Cadman, D. Gor, M. Dempsey, M. Walters, A. Candlin, M. Tisdale, P. J. Morley, I. J. Owens, R. J. Fenton, A. P. Lewis, E. C. J. Claas, G. F. Rimmelzwaan, R. De Groot, and A. D. M. E. Osterhaus. 2000. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44:78-87.
3. Burmeister, W. P., and P. M. Colman. 1992. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11:49-56.
4. Buxton, R. C., B. Edwards, R. R. Juo, J. C. Voyta, M. Tisdale, and R. C. Bethell. 2000. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280:291-300.
5. Gubareva, L. V., M. N. Matrosovich, M. K. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
6. Gubareva, L. V., L. Kaiser, and F. G. Hayden. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-835.
7. Guvareva, L. V., L. Kaiser, M. N. Matrosovich, Y. Soo-Hoo, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
8. Ives, J. A. L., J. A. Carr, D. B. Mendel, C. Y. Tai, R. Lambkin, L. Kelly, J. S. Oxford, F. G. Hayden, and N. A. Roberts. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir. Res. 55:307-317.
9. Jackson, H. C., N. Roberts, M. Z. Wang, and R. Belshe. 2000. Management of influenza; use of new antivirals and resistance perspective. Clin. Drug Investig. 20:447-454.
10. Kati, W. M., D. Montgomery, R. Carrick, L. Gubareva, C. Maring, K. McDaniel, K. Steffy, A. Molla, F. Hayden, D. Kempf, and W. Kohlbrenner. 2002. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46:1014-1021.
11. McKimm-Breschkin, J. L., T. J. Blick, A. Sahasrabudhe, T. Tiong, D. Marshall, G. J. Hart, R. C. Bethell, and C. R. Penn. 1996. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40:40-46.
12. McKimm-Breschkin, J. L. 2000. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antivir. Res. 47:1-17.
13. Mendel, D. B., C. Y. Tai, P. A. Escarpe, W. Li, R. W. Sidwell, J. H. Huffman, C. Sweet, K. J. Jakeman, J. Merson, S. A. Lacy, W. Lew, M. A. Williams, L Zhang, M. S. Chen, N. Bischofberger, and C. U. Kim. 1998. Oral administration of a prodrug of the influenza virus inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:640-646.
14. Potier, M., L. Mameli, M. Bélisle, L. Dallaire, and S. B. Melaņon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl α-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
15. Reyes, M., N. S. Subedar, J. M. Graber, R. Nisenbaum, N. T. Wetherall, K. Fukuda, W. C. Reeves, et al. 2003. Acyclovir-resistant genital herpes among persons attending STD and HIV clinics. Arch. Int. Med. 163:76-80.
16. Roberts, N. 2001. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos. Trans. R. Soc. Lond. B 356:1895-1897.
17. Tai, C. Y., P. A. Escarpe, R. W. Sidwell, M. A. Williams, W. Lew, H. Wu, C. U. Kim, and D. B. Mendel. 1998. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:3234-3241.
18. Tisdale, M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
19. Varghese, J. N., and P. M. Colman. 1991. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J. Mol. Biol. 221:473-486.
20. von Itzstein, M., W. Y. Wu, G. B. Kok, M. S. Pegg, J. C. Dyason, B. Jin, T. Van Phan, M. L. Smythe, H. F. White, S. W. Oliver, P. M. Colman, J. N. Varghese, D. M. Ryan, J. M. Woods, R. C. Bethell, V. J. Hotham, J. M. Cameron, and C. R. Penn. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:401-402.
21. Zambon, M., and F. G. Hayden. 2001. Position statement: global neuraminidase inhibitor susceptibility network. Antivir. Res. 49:147-156.